22nd Sep 2008 12:00
|
For immediate release |
22 September 2008 |
ABCAM PLC
("Abcam" or "the Company")
Director Exercise of Options
Cambridge UK, 22 September 2008: Abcam plc announces that on 19 September 2008 Jim Warwick exercised options over 32,000 ordinary shares in the Company at an exercise price of £0.50 per share. The options were granted under the First Abcam plc EMI Option Scheme.
Following this transaction Jim Warwick has an interest in 868,200 shares representing 2.48% of the Company's issued share capital.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeff Iliffe, Chief Financial Officer www.abcam.com |
|
|
Numis Securities |
+ 44 (0) 20 7776 1500 |
|
Nominated Adviser - Michael Meade/Nick Westlake Corporate Broking - James Black |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Mary-Jane Johnson |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 45,000 products, most of which are antibodies, from over 200 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs approximately 180 staff in its three operating companies.
Related Shares:
ABC.L